Login to Your Account



Biotie Closes Eventful Year with European Filing of Nalmefene

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 28, 2011
Biotie Therapies Oyj closed out the year exactly as planned – with a product undergoing regulatory review in Europe. Development partner H. Lundbeck A/S disclosed on Dec. 21 that the European Medicines Agency (EMA) had accepted for review its marketing authorization application (MAA) for nalmefene to treat alcohol dependence.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription